Data Vantage: CVS invests in Biofourmis, Lazada and Moladin bag new funding

Healthtech unicorn Biofourmis received nearly $27 million in equity funding last week as part of a $300 million Series D round announced in April.

US healthcare company CVS Health invested $25 million in the round, while another US-based investor put in nearly $2 million. The latest capital injection adds to the $150 million Biofourmis received earlier from General Atlantic.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter